Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other Accumulated Expenses: 2011-2024

Historic Other Accumulated Expenses for Anika Therapeutics (ANIK) over the last 12 years, with Dec 2024 value amounting to $765,000.

  • Anika Therapeutics' Other Accumulated Expenses rose 98.41% to $750,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $750,000, marking a year-over-year increase of 98.41%. This contributed to the annual value of $765,000 for FY2024, which is 126.33% up from last year.
  • According to the latest figures from FY2024, Anika Therapeutics' Other Accumulated Expenses is $765,000, which was up 126.33% from $338,000 recorded in FY2023.
  • In the past 5 years, Anika Therapeutics' Other Accumulated Expenses ranged from a high of $1.1 million in FY2021 and a low of $338,000 during FY2023.
  • Over the past 3 years, Anika Therapeutics' median Other Accumulated Expenses value was $510,000 (recorded in 2022), while the average stood at $537,667.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first slumped by 51.84% in 2022, then skyrocketed by 126.33% in 2024.
  • Over the past 5 years, Anika Therapeutics' Other Accumulated Expenses (Yearly) stood at $996,000 in 2020, then climbed by 6.33% to $1.1 million in 2021, then plummeted by 51.84% to $510,000 in 2022, then tumbled by 33.73% to $338,000 in 2023, then spiked by 126.33% to $765,000 in 2024.